We observed a decrease in the expression of CCL2 in PBMCs, hCMEC/D3 cells and U87i cells in the BBB model with PBMCs from moderate AD patients compared to mild AD patients, which could be used as a potential biomarker to discriminate later stages of AD. This evidence concerns the gene CCL2 and Alzheimer disease.